0001209191-20-024672.txt : 20200416
0001209191-20-024672.hdr.sgml : 20200416
20200416173321
ACCESSION NUMBER: 0001209191-20-024672
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200414
FILED AS OF DATE: 20200416
DATE AS OF CHANGE: 20200416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCANGOS GEORGE A
CENTRAL INDEX KEY: 0001202102
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 20797241
MAIL ADDRESS:
STREET 1: C/O EXELIXIS INC
STREET 2: 170 HARBOR WAY
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94083
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-14
0
0001706431
Vir Biotechnology, Inc.
VIR
0001202102
SCANGOS GEORGE A
C/O VIR BIOTECHNOLOGY, INC.
499 ILLINOIS STREET, SUITE 500
SAN FRANCISCO
CA
94158
1
1
0
0
President and CEO
Common Stock
2020-04-14
4
J
0
236806
29.56
D
1907329
I
See footnote
Common Stock
2020-04-14
4
J
0
236806
29.56
A
4713559
D
This transaction represents a substitution of assets in which 236,806 shares of the Issuer's common stock were transferred to the reporting person from the George A. Scangos 2018 Annuity Trust dated August 30, 2018 (the "GRAT") in exchange for other assets. The reporting person was the beneficial owner of the shares while they were held by the GRAT and remains the beneficial owner of the shares following their withdrawal from the GRAT. The reporting person believes that the transfer was exempt under Rule 16a-13 under the Securities Exchange Act of 1934.
Represents the average of the reported high and low per share prices for the Issuer's common stock on the date of the transaction.
The shares are held in the name of the GRAT, of which the reporting person and his spouse are trustees.
The total number of shares of common stock reported herein as directly owned includes 78,087 shares previously reported as indirectly owned through the GRAT and subsequently distributed to the reporting person in accordance with the terms of the GRAT.
/s/ Howard Horn, Attorney-in-Fact
2020-04-16